Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902385 | 1.00 | TDP1 (0.53) | TDP1CA1CA2CA7CA9 | |
| SCHEMBL3899157 | 1.00 | TDP1 (0.53) | TDP1CA1CA2CA7CA9 | |
| SCHEMBL32669044 | 1.00 | TDP1 (0.53) | TDP1CA1CA2CA7CA9 | |
| SCHEMBL133184 | 0.98 | TDP1 (0.55) | TDP1CA1CA2CA7CA9 | |
| SCHEMBL29757301 | 0.90 | TDP1 (0.56) | TDP1CA1CA2CA7CA9 | |
| SCHEMBL437165 | 0.87 | TDP1 (0.44) | TDP1CA1CA2CA7CA9 | |
| SCHEMBL439895 | 0.86 | CA1 (0.42) | TDP1CA1CA2CA7CA9 | |
| SCHEMBL3690008 | 0.86 | CA1 (0.42) | TDP1CA1CA2CA7CA9 | |
| SCHEMBL7524404 | 0.86 | CA1 (0.42) | TDP1CA1CA2CA7CA9 | |
| SCHEMBL31626283 | 0.86 | CA1 (0.42) | TDP1CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114903848-A | Transdermal preparation | 阿根塔创新有限公司 | 2022-08-16 | — | — | CN | claimed |
| US-20220202938-A1 | TRANSDERMAL FORMULATIONS | ARGENTA INNOVATION LIMITED (NZ) | 2022-06-30 | — | — | US | claimed |
| EP-3954363-A1 | TRANSDERMAL FORMULATIONS | Argenta Innovation Limited (NZ) | 2022-02-16 | — | — | EP | claimed |
| CN-106604971-B | Method for preparing aminosiloxane polymer nanoemulsion | 瓦克化学股份公司 | 2020-10-27 | — | — | CN | claimed |
| US-10329387-B2 | Process for making an aminosiloxane polymer nanoemulsion | WACKER CHEMIE AG (DE) | 2019-06-25 | — | — | US | claimed |
| EP-3250672-B1 | SILICONE NANOEMULSION COMPRISING C3-C6 ALKYLENE GLYCOL ALKYL ETHER | PROCTER & GAMBLE (US) | 2018-12-12 | — | — | EP | claimed |
| US-10150844-B2 | Process for making an aminosiloxane polymer nanoemulsion | WACKER CHEMIE AG (DE) | 2018-12-11 | — | — | US | claimed |
| EP-3250672-A1 | SILICONE NANOEMULSION COMPRISING C3-C6 ALKYLENE GLYCOL ALKYL ETHER | The Procter & Gamble Company (US) | 2017-12-06 | — | — | EP | claimed |
| US-20170247515-A1 | PROCESS FOR MAKING AN AMINOSILOXANE POLYMER NANOEMULSION | WACKER CHEMIE AG (DE) | 2017-08-31 | — | — | US | claimed |
| CN-107075126-A | The method for preparing amino silicone polymer nanoemulsions | 瓦克化学股份公司 | 2017-08-18 | — | — | CN | claimed |
| WO-2000022662-A1 | INHIBITION OF TITANIUM CORROSION | EKC TECHNOLOGY, LTD (GB) | 2000-04-20 | — | — | WO | claimed |
| US-5888308-A | Process for removing residue from screening masks with alkaline solution | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 1999-03-30 | — | — | US | claimed |
| EP-0485161-B1 | Stripping compositions and method of stripping resists from substrates | EKC TECHNOLOGY INC (US) | 1999-01-27 | — | — | EP | claimed |
| US-5381807-A | Semiconductor, polymer coatings | EKC TECHNOLOGY, INC. (US) | 1995-01-17 | — | — | US | claimed |
| US-5279771-A | Removal photoresist from substrate | EKC TECHNOLOGY, INC. (US) | 1994-01-18 | — | — | US | claimed |
| EP-0485161-A1 | Stripping compositions and method of stripping resists from substrates | EKC TECHNOLOGY, INC. (US) | 1992-05-13 | — | — | EP | claimed |
| US-4985519-A | FLUOROOLEFIN, VINYL ESTER, HYDROXYL-CONTAINING ALLYL ETHER, AND CARBOXYL-CONTAINING MONOMER | CENTRAL GLASS COMPANY, LIMITED (JP) | 1991-01-15 | — | — | US | claimed |
| US-4808235-A | SPRAYING BLADES WITH MIXTURES OF GLYCOL ETHERS, ADD WCTS OR POLYETHERS; ON-LINE | THE DOW CHEMICAL COMPANY (US) | 1989-02-28 | — | — | US | claimed |
| EP-0275987-A2 | Composition and method for cleaning gas turbine compressors | THE DOW CHEMICAL COMPANY (US) | 1988-07-27 | — | — | EP | claimed |
| US-4626453-A | Coating compositions and method for improving the properties of coated substrates | COATINGS FOR INDUSTRY, INC. (US) | 1986-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202938-A1 | TRANSDERMAL FORMULATIONS | NAPEPLD, CYP8B1, TSLP | TDP1 1560/4885CA1 2054/4885CA2 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.